Structural analysis and luminescence studies of Ce3+: Dy3+ co-doped calcium zinc gadolinium borate glasses using EXAFS

Publication date: Available online 17 January 2020Source: Radiation Physics and ChemistryAuthor(s): R. Rajaramakrishna, Y. Ruangtaweep, S. Sattayaporn, P. Kidkhunthod, S. Kothan, J. KaewkhaoAbstractCe3+: Dy3+- codoped calcium zinc gadolinium borate glasses were synthesized by traditional melt quenching technique. These glasses after synthesizing they were characterized through density, molar volume, refractive index, FTIR, absorption spectra, photoluminescence properties, structural studies using XANES/EXAFS and life time profile analysis. XANES spectra of Gd LIII-edge and Dy LIII-edge for 20CaCO3 - 20 ZnO - 10Gd2O3 - 49.5B2O3 - 0.5Dy2O3 (C2) and 20CaCO3 - 20 ZnO - 10Gd2O3 – 49B2O3 - 0.5Dy2O3 - 0.5CeF3 (D) glass showed absorption edge at 7249.8 eV and 7795.7 eV respectively confirming the presence of Gd3+ and Dy3+ ions. Ce-LIII edge for D glass shows peaks at ∼ 5728 eV confirming the presence of Ce3+. The Judd-Ofelt (JO) theory investigations have been applied for Dy3+ ions to calculate the Judd-Ofelt (JO) intensity parameters and found that the trend follows Ω2> Ω4> Ω6. The ionic nature of RE3+-O were evaluated by using bonding parameter (δ) value for C2 and D glass and found to be -0.0076 and -0.0102. Radiative properties were subsequently estimated using JO parameters and investigated radiative transition probabilities (AR), stimulated emission cross section (σR) and branching ratio (βR). The photoluminescence and ra...
Source: Radiation Physics and Chemistry - Category: Physics Source Type: research

Related Links:

AbstractBackgroundPrevious studies have identified that patients withEGFR mutations tend to have better responses to targeted therapy, as well as chemotherapy; however, the effect of genetic alterations in terms of radiotherapy (RT) ‐related outcomes has not been fully assessed. We studied the impact of common non‐small cell lung cancer (NSCLC) genetic alterations (EGFR,ALK andKRAS) in relation to objective response rate (ORR) to RT in patients with brain metastases.MethodsFrom 2009 –2015, 153 patients with an available genotyping status were treated with whole‐brain irradiation (WBI) before receiving systemic ...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsEndostar delivered by CIV with CCRT may be a better option than IV in terms of potential survival and safety for unresectable stage III NSCLC.Key pointsSignificant findings of the study Endostar delivered by continuous intravenous pumping might achieve more favorable survival over intravenous injection and reduce adverse hematological reactions in patients with unresectable stage III NSCLC treated with Endostar combined with CCRT.What this study adds The administration route of recombinant human endostatin is also one key factor for survival and safety to consider when treating patients with unresectable stage III NSCLC.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsThe use of osimertinib immediately after nivolumab significantly increased the frequency of grade 3 or higher hepatotoxicity in patients with advanced NSCLC harboringEGFR mutation acquired T790M resistance.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Authors: Dietrich DE, Bode L, Spannhuth CW, Hecker H, Ludwig H, Emrich HM Abstract BACKGROUND: Whether Borna disease virus (BDV-1) is a human pathogen remained controversial until recent encephalitis cases showed BDV-1 infection could even be deadly. This called to mind previous evidence for an infectious contribution of BDV-1 to mental disorders. Pilot open trials suggested that BDV-1 infected depressed patients benefitted from antiviral therapy with a licensed drug (amantadine) which also tested sensitive in vitro. Here, we designed a double-blind placebo-controlled randomized clinical trial (RCT) which cross-lin...
Source: BMC Pharmacology and Toxicology - Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research
Date: Friday, 02 28, 2020; Speaker: Jonathan Wasserman, Staff Physician, SickKids; BG 10-CRC; FAES 1&2
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Tuesday, 03 03, 2020; Speaker: TBD, TBD; Dr. Jeremy Veenstra-VanderWeele, Columbia University; Building: Building 10 (Clinical Center); Lipsett Auditorium; CME Credit
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Tuesday, 03 10, 2020; Speaker: TBD, TBD; Dr. Jeff Elias, University of Virginia School of Medicine; Building: Building 10 (Clinical Center); Lipsett Auditorium; CME Credit
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Tuesday, 03 10, 2020; Speaker: Staff NIH Library; Building: Building 10 (Clinical Center); NIH Library Training Room
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Wednesday, 03 11, 2020; Speaker: Staff NIH Library; Building: Building 10 (Clinical Center); This class is presented as a webinar only; Videocast Event
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Thursday, 03 12, 2020; Speaker: BTRIS instructor; Building: Building 10 (Clinical Center); NIH Library Training Room
Source: NIH Calendar of Events - Category: American Health Source Type: events
More News: Calcium | Chemistry | Physics | Study | Zinc